Trials / Completed
CompletedNCT06118866
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo-Q2W | placebo, 0mg，SC，Q2W，12 cycles |
| DRUG | HMI-115-120mg-Q4W | HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle) |
| DRUG | HMI-115-240mg-Q4W | HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle) |
| DRUG | HMI-115, 240mg-Q2W | HMI-115, 240mg，SC，Q2W，12 cycles |
Timeline
- Start date
- 2023-09-11
- Primary completion
- 2024-08-26
- Completion
- 2024-11-28
- First posted
- 2023-11-07
- Last updated
- 2025-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06118866. Inclusion in this directory is not an endorsement.